Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Fineline Cube Jul 10, 2026
Company Drug

Innovent’s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau

Fineline Cube Jul 9, 2025

China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with...

Company Deals

NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies

Fineline Cube Jul 9, 2025

China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for SHR-2173 in Primary Membranous Nephropathy

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

J&J Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

Fineline Cube Jul 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a supplemental New...

Company Drug

Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants

Fineline Cube Jul 9, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic...

Company Drug

Jiangsu Hengrui Gains NMPA Clinical Clearance for HRS-9821 in COPD Treatment

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Policy / Regulatory

NMPA Updates Review Procedures for Conditional Drug Marketing Approval Applications

Fineline Cube Jul 9, 2025

The National Medical Products Administration (NMPA) this week released a revised draft proposal for the...

Company Medical Device

Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation

Fineline Cube Jul 9, 2025

US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for...

Company Drug

HutchMed Announces First Commercial Shipments of Tazverik Across China

Fineline Cube Jul 9, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across...

Company Deals Medical Device

Shenzhen Concemed Medtech Secures Hundreds of Millions in Series A+ Funding for Endoscopy Expansion

Fineline Cube Jul 8, 2025

Shenzhen Concemed Medical Technology Co., Ltd., a China-based endoscope specialist, has reportedly secured “hundreds of...

Company Drug

RemeGen Submits New Indication Application for Disitamab Vedotin in Urothelial Carcinoma

Fineline Cube Jul 8, 2025

RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) in China has...

Company Drug

Grand Pharma’s SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC

Fineline Cube Jul 8, 2025

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR-Spheres Y-90 resin microspheres (SIR-Spheres), a...

Company Drug

Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema

Fineline Cube Jul 8, 2025

German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...

Company Deals

GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha

Fineline Cube Jul 8, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced the completion of its acquisition of BP Asset IX, a...

Company Deals

Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence

Fineline Cube Jul 8, 2025

China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals....

Policy / Regulatory

NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 8, 2025

The National Medical Products Administration (NMPA) has released the 93rd batch of reference drugs for...

Company Deals Drug

Roche’s Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases

Fineline Cube Jul 8, 2025

Roche’s Japan-based subsidiary Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced this week a joint research...

Company Deals

CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK

Fineline Cube Jul 8, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced a licensing agreement with Istituto Gentili S.R.L., granting the...

Company Drug

Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer

Fineline Cube Jul 8, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Drug

Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis

Fineline Cube Jul 8, 2025

Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that it has received clinical approval...

Posts pagination

1 … 157 158 159 … 693

Recent updates

  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
  • Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.